News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Yan Leyfman: New Data – CAR-T Outcomes in Extranodal DLBCL 
Yan Leyfman
Jun 25, 2025, 03:19

Yan Leyfman: New Data – CAR-T Outcomes in Extranodal DLBCL 

Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:

“New Data: CAR-T Outcomes in Extranodal DLBCL 
Extranodal (EN) DLBCL has long been linked to worse survival, but how do these patients fare after CAR-T therapy? A new multi-center study sheds light:
  •  218 patients with EN DLBCL treated with CAR-T in the relapsed/refractory setting
  •  Most common EN sites: Skin/soft tissue (25%), Bone (22%), Lung (17%)
  •  Overall Response Rate (ORR): 62% | Complete Response Rate (CRR): 40%
  •  Median PFS: 4 months | Median OS: 25.7 months
  •  High-risk factors for worse OS: ≥3 prior therapy lines, bulky disease, liver/pancreas involvement
CRS and ICANS were consistent with known CAR-T safety profiles. Future studies are needed to optimize CAR-T outcomes in high-risk EN DLBCL subgroups, especially those with hepatobiliary involvement.”

Title: Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study

Authors: Frederique St-Pierre, Subodh Bhatta, Peter G. Doukas, Madeline Jenkin, Kaitlin Annunzio, Alexandra E. Rojek, Alyssa Gibson, Yun Kyoung Tiger, Brittany McCall, Khaled Alhamad, Alec Hansen, Juan P. Alderuccio, Olutobi Adewale, Keem Patel, Asaad Trabolsi, Izidore S. Lossos, Lindsey Fitzgerald, Thomas A. Ollila, Matthew J. Matasar, Justin Kline, Reem Karmali, Narendranath Epperla

Read the Full Article.

Yan Leyfman

More posts featuring Yan Leyfman on OncoDaily.

Alec Hansen Alexandra E. Rojek Alyssa Gibson Asaad Trabolsi Brittany McCall cancer Frederique St-Pierre Izidore S. Lossos Juan P. Alderuccio Justin Kline Kaitlin Annunzio Keem Patel Khaled Alhamad Lindsey Fitzgerald Madeline Jenkin Matthew J. Matasar Narendranath Epperla Olutobi Adewale OncoDaily Oncology Peter G. Doukas Reem Karmali Subodh Bhatta Thomas A. Ollila Yan Leyfman Yun Kyoung Tiger
Special Coverage
Positive
Jul 19, 2025, 07:24
Strengthening Public Health: Cyprus Donates Lifesaving Medicines to Botswana
Dialogues
Jul 19, 2025, 07:23
Empowering Oncologists: Evolving role of AI in Oncology
Drugs
Jul 19, 2025, 07:22
Datopotamab deruxtecan-dlnk (Datroway) 2025 Guides: What Patients Need to Know?
Insight
Jul 19, 2025, 07:21
Wafik El-Deiry: Collaboration in US and Global Fight Against Cancer
Drugs
Jul 19, 2025, 07:08
Datopotamab Deruxtecan-dlnk (Datroway) Updates 2025: Uses in cancer, Side effects, Dosage, Expectations and More
Blog
Jul 19, 2025, 02:39
Alisher Kahharov: Training at the Prestigious Saint-Louis Hospital in Paris
Blog
Jul 19, 2025, 02:07
Bernard A. Fox: Back in Taiwan - Sharing the Next Frontier in Cancer Immunotherapy at Grand Rounds
Blog
Jul 19, 2025, 02:00
Akash Maniam: How Best to De-Escalate Excellent Responders and Intensify Those Who Don't
Career
Jul 18, 2025, 22:12
Sosipatros Boikos Joins the Life Raft Group As An External Consultant Medical Oncologist
Blog
Jul 18, 2025, 21:37
Zeynep Irem Ozay: Presentation by Ruchi Agarwal on Global Disparities in Clinical Trial Availability for Renal Cell Carcinoma
Insight
Jul 18, 2025, 21:36
Major disparities in access to Molecular Tumour Boards - Lung Cancer Europe
Oncolibrary
Jul 18, 2025, 21:35
Top 5 AI Tools for Medical Oncologists